Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey
Ann Oncol
.
2021 May;32(5):673-674.
doi: 10.1016/j.annonc.2021.01.066.
Epub 2021 Jan 30.
Authors
J Barrière
1
,
J Gal
2
,
B Hoch
3
,
O Cassuto
4
,
A Leysalle
5
,
E Chamorey
2
,
D Borchiellini
6
Affiliations
1
Department of Medical Oncology, Clinique Saint Jean, Cagnes-sur-Mer, France. Electronic address: j.barriere@polesantesaintjean.fr.
2
Department of Biostatistics and Epidemiology, Centre Antoine Lacassagne, Nice, France.
3
Department of Medical Oncology, Centre Azuréen de Cancérologie, Mougins, France.
4
Department of Medical Oncology, Clinique Saint George, Nice, France.
5
Department of Medical Oncology, Clinique Saint Jean, Cagnes-sur-Mer, France.
6
Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
PMID:
33529740
PMCID:
PMC7846886
DOI:
10.1016/j.annonc.2021.01.066
No abstract available
Publication types
Letter
MeSH terms
COVID-19 Vaccines
COVID-19*
Cross-Sectional Studies
Humans
Neoplasms*
SARS-CoV-2
Vaccination
Substances
COVID-19 Vaccines